Welcome Dr. Anke Fuchs as new Research Group Leader at CRTD

CRTD welcomes Dr. Anke Fuchs as a new research group leader. Her group develops novel and individualized cell-based therapeutics from which leukaemia patients after stem cell transplantation with severe inflammatory complications can benefit. In addition to the CRTD, Dr. Anke Fuchs is supported by the Mildred Scheel Early Career Center, which enables medical- scientists and clinician scientists to carry out translational projects in order to apply the latest results from basic research to everyday clinical practice as quickly as possible.

Dr. Anke Fuchs has been associated with the CRTD for many years: In 2012, she did her doctorate (PhD) in the research group of Prof. Ezio Bonifacio and received the CRTD Best Dissertation Award. As a postdoc, she continued her research in the field of autoimmunity and type 1 diabetes at the CRTD. Since 2015, she has worked as project leader for clinical translation between CRTD and the Medical Clinic I of the University Hospital Carl Gustav Carus, Dresden. Dr. Anke Fuchs received the Young Investigator Award of the International Society of Cellular Therapy (ISCT) in 2017 and was a fellow of the Maria-Reiche Mentoring Program for female scientists of the TU Dresden in 2017/18. With her new research group, she wants to conduct a clinical trial on the efficiency of automated isolated and expanded regulatory T cells (Treg) in stem cell transplanted leukaemia patients with chronic inflammatory reactions. In addition, cell therapies with further immune cells that hold promise for cancer, immunosuppressed patients or autoimmune diseases will be developed and successively translated to clinical practice. Detailed information on the research area and research goals of Dr. Anke Fuchs can be found here.

"With my new research group, I will dedicate myself to the close integration of research and clinical practice. The research network of the CRTD, its Good Manufacturing Practice (GMP) Facility - a technology platform for the production of cellular therapeutics - and the close interaction with the University Hospital offer ideal opportunities for this," says Dr. Anke Fuchs, who will expand her group within the coming months.